Date: 2016-07-26
Type of information: Licensing agreement
Compound: CNTO 7160
Company: Janssen Sciences Ireland, a J&J company (USA - NJ) GSK (UK)
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Type agreement: licensing
Action mechanism: monoclonal antibody. CNTO 7160 is an anti-IL-33R monoclonal antibody. It prevents interleukin-33 from binding to the ST2 receptor (IL-33R) and could be applicable to a broad spectrum of severe asthmatic populations. There is strong human genetic evidence and target biology linking the IL-33 pathway to asthma and regulation of inflammatory cells known to be important in asthma, including neutrophils and eosinophils.
Disease: asthma
Details: * On July 27, 2016, GSK announced that it has entered into an exclusive, worldwide licence agreement with Janssen Sciences Ireland UC for CNTO 7160, an anti-IL-33R monoclonal antibody currently in phase I clinical development. The agreement covers all therapeutic fields. Under the terms of the agreement, GSK will assume all development, manufacturing and commercialisation activities worldwide with the exception of the ongoing phase I study, which Janssen will continue to run through to completion
Financial terms: Janssen will receive up to £175 million comprising an upfront payment, and development and first commercial sales milestones, in addition to tiered royalties on sales and further considerations contingent on future sales performance.
Latest news:
